Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Financial News
Currencies
Commodities
Companies
Central Banks
Dmytro Kharkov
Dmytro Kharkov

Esperion Therapeutics to acquire Corstasis Therapeutics, expands cardiovascular portfolio with Enbumyst nasal spray

Esperion Therapeutics to acquire Corstasis Therapeutics, expands cardiovascular portfolio with Enbumyst nasal spray
Esperion acquires Corstasis, adds Enbumyst

Esperion Therapeutics has reached a definitive agreement to acquire Corstasis Therapeutics, marking a strategic move to expand its cardiovascular franchise.

The deal will add Enbumyst, a bumetanide nasal spray, to Esperion Therapeutics product portfolio. This acquisition aligns with the company's strategy to enhance its position in cardiovascular therapies through targeted innovation and new product offerings.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

CBDC ban: Why the U.S. does not need a digital dollar
  • By Eugene Komchuk
  • 19 hours ago
CBDC ban: Why the U.S. does not need a digital dollar
Editors' Picks
Bitcoin price prediction and Bollinger Bands: Can BTC recover after falling to $63,000?
  • By Mikhail Vnuchkov
  • Yesterday
Bitcoin price prediction and Bollinger Bands: Can BTC recover after falling to $63,000?
Editors' Picks
FIFA World Cup on blockchain: Where football meets crypto
  • By Oleg Tkachenko
  • 22.06.2026
FIFA World Cup on blockchain: Where football meets crypto
Editors' Picks
All Editors' Top Picks

Latest Esperion News

Esperion Therapeutics launches recruitment drive to advance cardiovascular care
  • By Ashutosh Sureka
  • 22.06.2026
Esperion Therapeutics launches recruitment drive to advance cardiovascular care
Companies
#Esperion
New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event
  • By Igor Krasulya
  • 26.05.2026
New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event
Companies
#Esperion
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization
  • By Dmytro Kharkov
  • 14.05.2026
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization
Companies
#Esperion
All Esperion News
  • Eugene Komchuk
  • 19 hours ago
CBDC ban: Why the U.S. does not need a digital dollar
  • Mikhail Vnuchkov
  • Yesterday
Bitcoin price prediction and Bollinger Bands: Can BTC recover after falling to $63,000?
  • Oleg Tkachenko
  • 22.06.2026
FIFA World Cup on blockchain: Where football meets crypto
  • Pavlo Kot
  • 21.06.2026
Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged
  • Pavlo Kot
  • 20.06.2026
Blockchain nation in crisis: How a power struggle split Liberland
  • Yulia Slavina
  • 45 min ago
Milwaukee and Hartford lead in home price growth, Lance Lambert notes
  • Hlib Chabaniuk
  • 45 min ago
Anas Alhajji: Market bets on higher Brent and WTI prices did not pay off
  • Hanna Syniavska
  • 1 hour ago
Protecting users and setting clear rules drives growth, Justin Sun notes
  • Dmytro Kharkov
  • 1 hour ago
Grant Cardone: Donald Trump will bring 10 year treasury yields down to make long mortgages affordable
  • Parshwa Turakhiya
  • 1 hour ago
James Pethokoukis: Brexit slowed Britain’s economic growth compared to U.S. and Euro area
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Eugene Komchuk
  • 13 hours ago
Binance ready to choose another EU country for MiCA license
Binance ready to choose another EU country for MiCA license
  • Olga Shendetskaya
  • 14 hours ago
Trump says Strait of Hormuz will remain open and toll-free
Trump says Strait of Hormuz will remain open and toll-free
  • Igor Krasulya
  • 16 hours ago
Indonesia requires licenses for financial influencers
Indonesia requires licenses for financial influencers
  • Hanna Syniavska
  • 18 hours ago
Cboe enters prediction markets with Mini-S&P 500 contracts
Cboe enters prediction markets with Mini-S&P 500 contracts
  • Olga Shendetskaya
  • 18 hours ago
U.S. stock futures waver as doubts grow around AI trade
U.S. stock futures waver as doubts grow around AI trade
Live News
  • Anton Kharitonov
  • Now
Google corrects after rally despite strong Alphabet results
  • Anton Kharitonov
  • Now
Microsoft remains under pressure from AI spending despite Azure growth
  • Mykhailo Ihnatenko
  • Now
Moderna rallies on vaccine progress as investors await revenue growth
  • Mykhailo Ihnatenko
  • Now
Intel's relative strength faces key test
  • Mykhailo Ihnatenko
  • Now
Micron earnings may determine Nvidia's next move
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR